{"id":"NCT03565887","sponsor":"RVL Pharmaceuticals, Inc.","briefTitle":"Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis","officialTitle":"A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-28","primaryCompletion":"2019-04-11","completion":"2019-04-22","firstPosted":"2018-06-21","resultsPosted":"2020-09-16","lastUpdate":"2020-09-16"},"enrollment":164,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Blepharoptosis"],"interventions":[{"type":"DRUG","name":"RVL-1201","otherNames":[]},{"type":"OTHER","name":"Vehicle ophthalmic solution","otherNames":[]}],"arms":[{"label":"RVL-1201 ophthalmic solution 0.1%","type":"EXPERIMENTAL"},{"label":"Vehicle ophthalmic solution","type":"PLACEBO_COMPARATOR"}],"summary":"Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.","primaryOutcome":{"measure":"Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group","timeFrame":"Mean change from Baseline (Day 1, Hour 0) compared with Day 1, (Hour 6), and Day 14 (Hour 2)","effectByArm":[{"arm":"RVL-1201 Ophthalmic Solution 0.1%","deltaMin":6.3,"sd":6.72},{"arm":"Vehicle Ophthalmic Solution","deltaMin":2.1,"sd":4.28}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":109},"commonTop":["Conjunctival hyperaemia","Punctate keratitis","Vital dye straining cornea present","Eye pain","Eye pruritus"]}}